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ABSTRACT
Objective: This study aimed to determine the effects of nanocurcumin on cardiomyopathy, assessed by the expression of B-type natriuretic peptide 
(BNP) mRNA in heart tissue.
Methods: Type 2 diabetic rats were induced with streptozotocin and nicotinamide. Nanocurcumin was orally administered (100 mg/kg/day) 
for 30 days. BNP-45 mRNA expression in the heart tissue was measured using quantitative reverse transcription-polymerase chain reaction and 
calculated using the Livak method.
Results: BNP-45 levels increased significantly (p<0.05) in diabetic rats compared with the normal group. Nanocurcumin treatment at a dose of 
100 mg/kg for 30 days significantly decreased BNP-45 expression levels (p<0.05) compared with diabetic rats without treatment.
Conclusion: Nanocurcumin may be beneficial in inhibiting the progression of diabetic cardiomyopathy by suppressing the expression of BNP-45.
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INTRODUCTION
Diabetes mellitus (DM) is a metabolic disease characterized by 
hyperglycemia caused by insulin secretion abnormalities [1]. In 
Indonesia, the prevalence of diabetes increased from 5.7% of the overall 
population in 2007–6.9% in 2013 [2]. This increased incidence of DM is 
most certainly accompanied by complications. Chronic hyperglycemia 
in patients with uncontrolled diabetes leads to the development of 
high levels of reactive oxygen species (ROS) and pro-inflammatory 
cytokines, which can cause cell dysfunction in various organs including 
heart tissue [3-5]. Indeed, diabetic cardiomyopathy is characterized 
by dilatation and hypertrophic myocardium, resulting in decreased 
systolic and diastolic ventricle function [5].
B-type natriuretic peptide (BNP) levels are considered an objective and 
specific measurement to diagnose and evaluate therapies for cardiac 
failure [6]. BNP is a specific cardiac neurohormone that increases 
in response to hypertrophy and dilatation of the myocardium [7,8]. 
Treatments for hypertrophic cardiomyopathy are still being developed 
and include herbal medicines. One such herbal medicine is curcumin, an 
active substance obtained from Curcuma longa, which is an indigenous 
plant of Indonesia [9]. Previous studies have shown that curcumin has 
anti-inflammatory, antioxidant, and antiproliferative properties [9-11]. 
Therefore, it may be promising as an adjunctive treatment of type 2 
diabetes by inhibiting its progression [11]. Unfortunately, the 
therapeutic usage of curcumin is limited due to its low bioavailability. 
However, a previous study has reported that the bioavailability of 
curcumin increases in the form of nanoparticles [12,13].
Previously, oral administration of nanocurcumin (100 mg/kg body weight 
per day for 30 days) appeared to suppress ROS levels in rats with diabetic 
cardiomyopathy [14]. However, no research on the effects of nanocurcumin 
on diabetic cardiomyopathy in rats has been conducted. Thus, this 
study aimed to investigate the effects of nanocurcumin on diabetic 
cardiomyopathy in rats induced with streptozotocin and nicotinamide, in 
an effort to enrich the use of Indonesian natural medicines.
This study aimed to analyze the effects of nanocurcumin on diabetic 
cardiomyopathy through the examination of BNP-45 mRNA expression 




RNA isolation, cDNA synthesis, and reverse transcription polymerase 
chain reaction (RT-PCR) kits were purchased from Roche.
Animals
Male Sprague-Dawley rats weighing 150–300 g, obtained from 
LITBANGKES (Jakarta, Indonesia), were used. The rats were kept in a 
room with constantly controlled temperature, humidity, and lighting. 
They were provided food and water ad libitum.
Nanocurcumin preparation
Nanocurcumin was obtained from PT. Nanotech Puspitek (Serpong, 
Indonesia). It was orally administered at a dose of 100 mg/kg body 
weight per day for 30 days.
Experimental design
The dosing and schedule of nanocurcumin treatment in rats has 
been described in a previous study [15]. The rats were divided 
into three groups: Normal, diabetic, and diabetic rats treated with 
nanocurcumin. Nanocurcumin was administered orally at a dose of 
100 mg/kg/day  for  30  days.  Rat  heart  tissue  was  stored  at  −80°C 
until analysis.
RNA isolation
Heart tissue was homogenized using an Ultra Turrax electric 
homogenizer. Total RNA was isolated from heart tissue homogenate 
using the TriPure® reagent (Roche) according to the manufacturer’s 
protocol. Isolated RNA concentration and purity were measured with a 
Nanodrop 2000 (Thermo Scientific).
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cDNA synthesis
The cDNA synthesis reaction was performed using a Transcriptor First 
Strand cDNA Synthesis Kit (Roche). The concentration and purity were 
measured spectrophotometrically at 260 nm using a Nanodrop 2000 
(Thermo Scientific).
Examination of BNP-45 mRNA expression
The mRNA expression of BNP-45 in heart tissue was measured by 
quantitative RT-PCR and calculated by the Livak method. RT-PCR was 
conducted using the FastStart Essential DNA Green Master (Roche) 
kit on a LightCycler Nano (Roche). Primers and temperatures used for 
amplification are presented in Table 1.
The expression of mRNA was automatically calculated by the software 
to get a threshold value (Ct). The value was then calculated by the Livak 
method based on 2–ΔΔCt to obtain the level of mRNA expression.
Production of heart homogenates for the determination of BNP-45 
levels
Whole heart tissues were cut and weighted at 100–120 mg and placed 
into a glass mortar. The mixture of tissue with phosphate-buffered 
saline at 9 times the volume, along with 5 µL of protease inhibitor 
solution, was homogenized using a mortar and pestle. The homogenate 
was centrifuged at 12,000×g for 15 min at 4°C, and the supernatant was 
obtained. Pellets were then washed by isopropanol and centrifuged 
at 7500×g for 5 min. RNase-free water was added after removing the 
supernatant,  and  the mixture was  incubated at 60°C  for 15 min. The 
RNA was then used for the preparation of cDNA using 4 μL of transcript 
reverse transcriptase reaction buffer, 0.5 μL RNAase inhibitor protector 
(40  U/μL),  2  μL  Deoxynucleotide  mix  (10  mM),  and  transcriptase 
reverse transcriptase (10 U/μL). The tube was placed in a thermal block 
cycler at 65°C for 10 min, 25°C for 10 min, and 55°C for 5 min.
Measurement of BNP-45 level
Measurement of BNP-45 levels was conducted using the RT-PCR method 
with the RT-PCR SYBR® Green Supermix kit.
Statistical analysis
The data obtained were analyzed using the Statistical Package for the 
Social Sciences version 20. One-way analysis of variance was used for 
comparisons among groups, followed by post hoc test least significant 
difference. p<0.05 was considered to be statistically significant.
RESULTS AND DISCUSSION
BNP-45 expression analysis results are depicted in Fig. 1. BNP-45 
levels increased significantly (p<0.05) in diabetic rats compared with 
the normal group. Nanocurcumin treatment at a dose of 100 mg/kg 
for 30 days significantly decreased BNP-45 expression levels (p<0.05) 
compared with diabetic rats without treatment.
Diabetic cardiomyopathy is a cardiovascular disorder characterized 
by chronic hyperglycemia in diabetic patients [3]. Accordingly, the 
myocardium becomes hypertrophied and dilated and increased BNP 
is secreted to maintain cardiovascular homeostasis. Indeed, BNP is 
a specific cardiac neurohormone that can be an objective and simple 
measurement for diagnosing and evaluating therapies for cardiac 
failure. Our results indicate that BNP-45 levels in diabetic rats were 
higher than in normal rats. This is likely because the diabetic rats had 
cardiomyopathy and the hypertrophic myocardium expressed BNP-45 
to a greater extent [15]. Hypertrophy causes myocardium stretching, 
which triggers the expressions of BNP into the bloodstream to maintain 
cardiovascular homeostasis. When the cardiovascular load increases 
and fails in overall function, the second line of protection will be 
activated to speedup BNP transcription. Therefore, levels of BNP mRNA 
in heart tissue will increase [16].
The progression of cardiomyopathy can be inhibited by administering 
an antioxidant [11,15]. One such antioxidant is curcumin, an active 
substance from Curcuma longa that has been proven to suppress 
the progression of type 2 DM [11]. In a previous study, curcumin in 
nanoparticles at a dose of 100 mg/kg for 30 days suppressed ROS levels 
in diabetic rats [15].
According to our results, oral treatment with nanocurcumin at a dose 
of 100 mg/kg for 30 days in diabetic rats resulted in lower mRNA BNP-
45 expression than diabetic rats that were not treated. This shows that 
the treatment of nanocurcumin decreased the expression of BNP-45 in 
rats experiencing cardiomyopathy. These findings are in accordance 
with previous research demonstrating significant improvement of 
heart tissue damage in rats treated for myopathy [15]. It is also in line 
with another study that confirmed that nanocurcumin is an antioxidant 
and anti-inflammatory with good cardiovascular effects, particularly 
in reducing migration and growth of uncontrolled vascular smooth 
muscle cells under hyperglycemic conditions [14].
CONCLUSION
Collectively, our findings indicate that nanocurcumin has beneficial 
effects in inhibiting the progression of diabetic cardiomyopathy by 
suppressing the expression of BNP-45 mRNA. Moreover, a dose of 
100 mg/kg for 30 days of nanocurcumin treatment significantly 
decreased BNP-45 expression levels. This shows that the treatment of 
nanocurcumin decreased the expression of BNP-45 in rats experiencing 
cardiomyopathy.
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